CNMD · CONMED Corp · Financials

$44.29 -1.43 (-3.13%) At close · Oct 30 Q2 2026 earnings call transcript

S&P 600 member Russell 2000 member Rebalance outlook locked

Market Cap

$1.32B

29.80M

Volume · Oct 30 404.1K Avg daily vol (3M) 385.17K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →

Revenue

$1.37B +5.2%

FY2025

Net Income

$47.06M -64.5%

FY2025

Gross Margin

54.59% -1.5pp

FY2025

Operating Margin

7.46% -7.9pp

FY2025

Diluted EPS

$1.51 -64.5%

FY2025

Operating Cash Flow

$170.69M +2.2%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2026 (G)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Revenue	+9.6%	+9.8%	+6.7%	$1.35B – $1.38B	$1.37B	$1.37B^G	$1.31B^G	$1.24B^G	$1.05B^G	$1.01B^G	$862.46M	$955.1M	$859.63M	$796.39M	$763.52M	$719.17M	$740.06M	$762.7M	$767.14M	$725.08M	$713.72M	$694.74M
Cost of Revenue	+9.6%	+9.2%	+6.3%	—	$580.95M	$624.25M	$573.98M	$568.5M	$474.23M	$442.6M	$402.16M	$430.38M	$390.52M	$365.35M	$355.19M	$337.47M	$336M	$350.29M	$361.3M	$350.14M	$348.34M	$357.41M
Gross Profit	+9.5%	+10.3%	+7.0%	—	$788.34M	$750.48M	$733.03M	$676.25M	$571.25M	$568.04M	$460.3M	$524.72M	$469.11M	$431.04M	$408.33M	$381.7M	$404.06M	$412.42M	$405.84M	$374.93M	$365.38M	$337.33M
Gross Margin	—	—	—	—	—	54.59%	56.08%	54.33%	54.64%	56.21%	53.37%	54.94%	54.57%	54.12%	53.48%	53.08%	54.6%	54.07%	52.9%	51.71%	51.19%	48.56%
Research & Development	+5.8%	+6.7%	+7.4%	—	$62.32M	$55.88M	$54.43M	$52.6M	$47.15M	$43.57M	$40.47M	$45.46M	$42.19M	$32.31M	$32.25M	$27.44M	$27.78M	$25.83M	$28.21M	$28.65M	$29.65M	$31.84M
General & Administrative	+11.1%	—	—	—	—	$131.96M	$117.46M	$111.24M	$96.11M	—	—	—	—	—	—	—	—	—	—	—	—	—
Selling, General & Administrative	+9.2%	+9.6%	+6.9%	—	$590.43M	$591.97M	$478.28M	$503.04M	$454.04M	$414.75M	$373.82M	$400.14M	$355.62M	$351.8M	$338.4M	$303.09M	$323.49M	$330.08M	$302.47M	$276.62M	$276.46M	$266.31M
Amortization of Intangibles	+1.5%	+0.6%	+10.8%	—	$35.3M	$35.2M	$34.7M	$35.2M	$33.7M	$33.3M	$34.2M	$32.3M	$23.2M	$21.3M	$20M	$12.6M	$13M	$13.7M	$13.8M	—	—	—
Restructuring Charges	—	—	—	—	—	—	—	—	—	—	—	—	—	$4.25M	$9.74M	$21.67M	$21.51M	$17.38M	—	—	—	—
Total Operating Expenses	+8.9%	+9.4%	+7.0%	—	$652.75M	$647.85M	$532.71M	$555.64M	$501.19M	$458.32M	$414.29M	$445.6M	$397.81M	$384.11M	$370.65M	$330.53M	$351.27M	$355.91M	$340.63M	$366.66M	$308.29M	$309.06M
Operating Income	+13.6%	+17.4%	+7.2%	—	$135.59M	$102.62M	$200.33M	$120.6M	$70.05M	$109.72M	$46.01M	$79.11M	$71.31M	$46.94M	$37.68M	$51.18M	$52.79M	$56.51M	$65.21M	$8.27M	$57.09M	$28.27M
Operating Margin	—	—	—	—	—	7.46%	15.33%	9.69%	6.7%	10.86%	5.33%	8.28%	8.29%	5.89%	4.93%	7.12%	7.13%	7.41%	8.5%	1.14%	8%	4.07%
Interest Expense	+2.5%	-6.7%	+17.8%	—	$33.45M	$31.09M	$37.3M	$39.78M	$28.91M	$35.49M	$44.05M	$42.7M	$20.65M	$18.2M	$15.36M	$6.03M	$6.11M	$5.61M	$5.73M	$6.68M	$7.11M	$7.09M
Gain on Sales of Real Estate	—	—	—	—	—	—	—	—	—	—	—	—	$0	$0	$1.89M	$0	$0	—	—	—	—	—
Pretax Income	—	+113.5%	+4.6%	—	$104.96M	$71.12M	$163.03M	$80.83M	-$70.86M	$73.11M	$1.6M	$31.23M	$50.65M	$28.73M	$19.38M	$45.14M	$46.68M	$50.63M	$59.48M	-$2.31M	$45.66M	$18.16M
Income Tax	+35.3%	—	+5.1%	—	$31.53M	$24.06M	$30.61M	$16.37M	$9.72M	$10.56M	-$7.91M	$2.61M	$9.8M	-$26.76M	$4.71M	$14.65M	$14.48M	$14.69M	$19M	-$3.06M	$15.31M	$6.02M
Net Income	—	+37.7%	+4.4%	—	$73.43M	$47.06M	$132.42M	$64.46M	-$80.58M	$62.54M	$9.52M	$28.62M	$40.85M	$55.49M	$14.66M	$30.5M	$32.19M	$35.94M	$40.48M	$752K	$30.35M	$12.14M
Net Margin	—	—	—	—	—	3.42%	10.13%	5.18%	-7.71%	6.19%	1.1%	3%	4.75%	6.97%	1.92%	4.24%	4.35%	4.71%	5.28%	0.1%	4.25%	1.75%
Comprehensive Income	—	+63.4%	+13.8%	—	$78.49M	$59.62M	$123.74M	$72.15M	-$84.24M	$72.02M	$5.11M	$25.08M	$40.14M	$64.94M	$10.03M	$16.43M	$9.94M	$45.95M	$39.25M	-$9.74M	$26.89M	$30.76M
EPS (Basic) USD/shares	—	+35.7%	+3.3%	—	$2.43	$1.52	$4.29	$2.10	-$2.68	$2.14	$0.33	$1.01	$1.45	$1.99	$0.53	$1.10	$1.17	$1.30	$1.43	$0.03	$1.06	$0.42
EPS (Diluted) USD/shares	—	+36.4%	+3.3%	$4.48 – $4.60*	$2.42	$1.51^G	$4.25^G	$2.04^G	-$2.68^G	$1.94^G	$0.32	$0.97	$1.41	$1.97	$0.52	$1.09	$1.16	$1.28	$1.41	$0.03	$1.05	$0.42
Shares Outstanding (Basic Avg) shares	+1.1%	+1.7%	+1.2%	—	—	31.04M	30.85M	30.67M	30.04M	29.16M	28.58M	28.33M	28.12M	27.94M	27.8M	27.65M	27.4M	27.72M	28.3M	28.25M	28.72M	29.07M
Shares Outstanding (Diluted Avg) shares	+1.2%	+1.1%	+1.1%	—	—	31.15M	31.15M	31.55M	30.04M	32.22M	29.46M	29.5M	28.89M	28.17M	27.96M	27.86M	27.77M	28.11M	28.65M	28.63M	28.91M	29.14M

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2025: $109.34M in buybacks, $307.12M in dividends.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balance	As of	Amount	Source
Finance lease liabilities	2026-09-30	USD 734,000	10-Q filed 2026-10-28
Long-term debt and lease obligations, including current maturities	2026-09-30	USD 815,866,000	10-Q filed 2026-10-28
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current long-term debt and lease obligations USD 180,109,000 Noncurrent long-term debt and lease obligations USD 635,757,000

Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

1.52×

Peer median 3.40×

EV/EBIT

15.40×

Peer median 23.49×

P/E (TTM)

18.30×

Peer median 29.37×

Peer medians compare against the 64 similar-size Medical Devices companies (of 156 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Geography (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
United States	$774,588,000	$748,224,000	$700,160,000	$578,953,000	$552,533,000	$482,064,000	$516,665,000	$448,648,000
EMEA	$264,654,000	$243,064,000	$226,253,000	$197,937,000	$189,695,000	$161,084,000	$182,549,000	$166,563,000
Asia Pacific	$208,722,000	$194,684,000	$197,401,000	$162,477,000	$171,218,000	$140,597,000	$160,610,000	$146,895,000
Americas Excluding the United States	$126,760,000	$121,043,000	$120,930,000	$106,105,000	$97,189,000	$78,714,000	$95,273,000	$97,528,000

By Product & Service (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
General Surgery	$800,126,000	$763,027,000	$711,586,000	$583,944,000	$572,211,000	$487,754,000	$491,775,000	$412,906,000
Orthopedic Surgery	$574,598,000	$543,988,000	$533,158,000	$461,528,000	$438,424,000	$374,705,000	$463,322,000	$446,728,000

Key facts CIK 816956 CUSIP 207410101 13F (30d) 86 filings 68 filers Visit website Investor relations